Skip to Main Content
Don't have an account? Create Account
Loading more articles
State Action

Judge Dan Polster of the U.S. District Court for the Northern District of Ohio rejected opioid companies’ motion to dismiss hundreds of state and local lawsuits against them, ordering litigation to proceed and for the parties to discuss a potential settlement.

view more »
State Action

A judge in the U.S. District Court for the Northern District of Texas sided with a group of Republican governors and attorneys general in 20 states who argued that the law's individual mandate is unconstitutional without the related tax penalty.

view more »
aca
State Action

Leaders in Colorado, Connecticut, Delaware, Minnesota, Nevada, New Mexico, Oregon, and Wisconsin have expressed interest in allowing individuals who cannot afford private health insurance to buy into the Medicaid program if they are otherwise ineligible.

view more »
State Action

Three new Democratic governors have vowed to move forward with Medicaid expansion in their states; Meanwhile, voters in Idaho, Nebraska, and Utah approved Medicaid expansion, while Montana voters rejected an initiative to extend the state's expansion past June 2019.

view more »
State Action

States have explored both traditional policy levers and novel approaches to manage Medicaid prescription drug costs, and many newly-elected governors have signaled that the issue is a policy priority.

view more »
State Action

America’s Essential Hospitals examines the multitude of lawsuits local, state, and federal governments are pursuing against opioid manufacturers and distributors for their role in the opioid crisis.

view more »
State Action

Vermonters will experience a 23 percent increase in marketplace premiums, while Tennesseans will see a 26 percent decrease; nationally, premiums will decrease 1 percent on average.

view more »
State Action

Colorado's new policy requires certain providers to report the acquisition cost of drugs purchased through the 340B Drug Pricing Program; Mississippi mandates that certain providers identify 340B-purchased drugs on medical and retail pharmacy claims.

view more »